Horizon Pharma (HZNP) has grown nearly 500% in price during the last year. This “boring” company is flying under the radar. With the recent acquisition of Vidar, the company will continue it's growing trend meaning investors can still benefit.
Using similar growth tactics as Horizon, Alliqua (ALQA) is a niche wound care player that should not be overlooked by investors making the same mistake. Alliqua is ramping up an acquisition strategy that is expected to deliver robust top line growth and as a result lead to price appreciation.
To find out more about these rather "boring", but lucrative companies: http://lastfinancier.com/